Redmile Group Sells 196,000 ADC Therapeutics Shares, Raising $75 Million in a Strategic Portfolio Shift

Redmile Group’s Recent Sell‑Off Signals a Shift in Investor Confidence

Redmile Group, LLC has moved decisively to divest a sizable block of ADC Therapeutics SA common stock, liquidating 196,229 shares at a weighted average of $3.75 on March 31, 2026. This sale is part of a broader pattern of Redmile‑managed vehicles—RedCo II Master Fund, L.P. and other private investment vehicles—selling over 12 million shares across four separate transactions between March 31 and April 2. The cumulative proceeds exceed $75 million, underscoring a substantial rebalancing of the investment group’s exposure to the Swiss‑based oncology firm.

The timing of the sell‑off is notable. ADC’s stock has already slipped 9.21 % for the year, falling from its 52‑week high of $4.98 to $3.80. Market sentiment around the company remains muted (buzz = 0.00 %), suggesting that the sale may not be driven by a sudden market shock but rather a deliberate portfolio optimization. Redmile’s historic transactions, mainly large purchases of pre‑funded warrants in June and October 2025, had positioned the group with a significant equity stake. The recent liquidation therefore represents a substantial reduction in ownership, potentially reflecting a reassessment of the company’s near‑term upside or a strategic shift to reallocate capital toward higher‑yield opportunities.

For investors, this insider activity raises several questions. First, the departure of a major investor could trigger a downward pressure on liquidity, especially if other holders follow suit. Second, Redmile’s exit may be interpreted as a confidence signal that the company’s valuation is over‑extended relative to its pipeline progress. Finally, the timing coincides with the company’s announcement of a new employee inducement grant, suggesting that ADC may be prioritizing talent acquisition over external capital retention. In a sector where pipeline milestones drive valuation, a reduction in institutional support could accelerate a valuation recalibration unless offset by breakthrough clinical data.

Redmile Group, LLC – A Profile of a Strategic Investor

Redmile Group, LLC operates through a network of private investment vehicles that focus on high‑growth biotech and clinical‑stage companies. Its transaction history reflects a two‑phase approach: first, large-scale purchases of pre‑funded warrants and equity to establish a foothold; second, opportunistic divestitures as the company matures or market conditions shift. The 2025 purchases—totaling over 30 million shares in warrants—demonstrate a willingness to commit substantial capital when valuation metrics appear favorable. However, the rapid conversion of that position into cash in early 2026 suggests a disciplined exit strategy, likely tied to predetermined return thresholds or portfolio rebalancing rules.

Redmile’s track record shows a preference for companies with clear therapeutic potential and a solid regulatory pathway. The firm’s willingness to engage with ADC Therapeutics, a clinical‑stage oncology developer, aligns with its broader mandate to back companies poised for commercialization. The recent sale, while sizeable, is not unprecedented; it mirrors Redmile’s own historical pattern of reallocating capital toward emerging opportunities in the biotech space.

What This Means for ADC’s Future

The confluence of Redmile’s sell‑off, the company’s ongoing employee incentive grant, and the broader market downturn for ADC suggests a transitional period. ADC’s clinical pipeline remains the primary engine of future value, yet the current share price contraction could be an opportunity for new investors seeking a discounted entry point. However, the company’s negative price‑earnings ratio (-3.24) and significant volatility underscore the inherent risk of betting on a clinical‑stage firm.

For existing shareholders, the key will be to monitor upcoming data releases and regulatory milestones. If ADC can deliver positive clinical outcomes or secure a commercial partnership, the stock may rebound, offsetting the dilution impact of Redmile’s exit. Conversely, a failure to meet expectations could reinforce the narrative of over‑valuation, further compressing the share price. Investors should weigh the potential upside of ADC’s innovative ADC platform against the recent loss of a major institutional backer, adjusting their exposure accordingly.